Table 1 Details of the data presented by the included studies
Study (first author) | Country | Study design | Total sample size | Case group | Etiology of IC condition | Type of vaccine | ||
|---|---|---|---|---|---|---|---|---|
No. of cases | Male% | Age (mean ± SD) (median [IQR]*) | ||||||
Addeo, A. | Switzerland and USA | Prospective cohort | 131 | 131 | 55 | 63 [55–69]* | Malignancy | n  = 30 (BNT162b2 (Pfizer/BionTech)) or n  = 93 (mRNA-1273 (Moderna)) |
Agbarya, A. | Israel | Cross-sectional | 355 | 140 | 54 | 65.3 ± 1.4 | Malignancy | BNT162b2 (Pfizer/BionTech) |
Agha, M. | USA | Prospective cohort | 67 | 67 | 52.2 | 71 [65–77]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Ammitzbøll, C. | Denmark | Retrospective cohort | 134 | 134 | 67.1 | NA | Autoimmune | BNT162b2 (Pfizer/BionTech) |
Benotmane, I. | France | Cross-sectional | 241 | 241 | 64.7 | 57.7 [49.3-67.6]* | Transplant | mRNA-1273 (Moderna) |
Benotmane, I. | France | Prospective cohort | 159 | 159 | 61.6 | 57.6 [49.6-66.1]* | Transplant | mRNA-1273 (Moderna) |
Bertrand, D. | France | Retrospective cohort | 55 | 45 | 51 | 63.5±16.3 | Autoimmune | BNT162b2 (Pfizer/BionTech) |
Boekel, L. | Netherlands | Prospective cohort | 921 | 632 | 33 | 63±11 | Autoimmune | ChAdOx1 nCoV-19 (AstraZeneca), BNT162b2 (Pfizer-BioNtech), CX-024414 (elasomeran; Moderna), and Ad.26.COV2.S (Janssen) |
Boyarsky, B. | USA | Prospective cohort | 1040 | 1012 | NA | 60.0 [45.7-68.1]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Boyarsky, B. | USA | Prospective cohort | 436 | 423 | 39 | 55.9 [41.3-67.4]* | Transplant | n  = 223 (BNT162b2 (Pfizer/BionTech)) or n  = 204 (mRNA-1273 (Moderna)) |
Boyarsky, B. | USA | Prospective cohort | 123 | 123 | 5 | 50 [41–61]* | Autoimmune | n  = 64 (BNT162b2 (Pfizer/BionTech)) or n  = 59 (mRNA-1273 (Moderna)) |
Boyarsky, B. | USA | Prospective cohort | 658 | 658 | 50 | NA | Transplant | n =100 (BNT162b2 (Pfizer/BionTech)) or n  = 99 (mRNA-1273 (Moderna)) |
Boyarsky, B. | USA | Prospective cohort | 737 | 737 | 42 | 56 [42–60]* | Transplant | n  = 12 (Ad26 (JANSSEN/JOHNSON&JOHNSON)) or n  = 725 (mRNA vaccine) |
Braun-Moscovici, Y. | Israel | Prospective cohort | 290 | 264 | 24 | 57.6 ± 13.18 | Autoimmune | BNT162b2 (Pfizer/BionTech) |
Cao, J. | USA | Retrospective cohort | 47 | 37 | 72.9 | 64 [50–69]* | Transplant | BNT162b2 (Pfizer/BionTech) or mRNA-1273 (Moderna) |
Chavarot, N. | France | Retrospective cohort | 97 | 97 | 58 | 63.5 [51–72]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Chavarot, N. | France | Retrospective cohort | 101 | 101 | 67.3 | 64 [53–73]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Chevallier, P. | France | Prospective cohort | 138 | 112 | 59.8 | 57 [20–75]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Chiang, T. P. | USA | Prospective cohort | 1039 | 1039 | 6.1 | NA | Autoimmune | n  = 45 (Ad26 (JANSSEN/JOHNSON&JOHNSON)) or n  = 994 (mRNA vaccine) |
Cohen, D. | Israel | Prospective cohort | 137 | 137 | 54.7 | 68.5 | Malignancy | BNT162b2 (Pfizer/BionTech) |
Cucchiari, D. | Spain | Prospective cohort | 148 | 117 | 67.3 | 59.0 ± 52.4 | Transplant | mRNA-1273 (Moderna) |
Danthu, C. | France | Prospective cohort | 159 | 74 | 61.1 | 64.8 ± 11.5 | Transplant | BNT162b2 (Pfizer/BionTech) |
Del Bello, A. | France | Retrospective cohort | 396 | 396 | 65 | 59 ± 15 | Transplant | BNT162b2 (Pfizer/BionTech) |
Easdale, S. | UK | Retrospective cohort | 55 | 55 | 61.8 | 50 [18–73]* | Transplant | n  = 21 (BNT162b2 (Pfizer/BionTech)) or n  = 34 (AstraZeneca ChAdOx1 nCoV-19 vaccine (AZ)) |
Ehmsen, S. | Denmark | Prospective cohort | 524 | 524 | NA | NA | Malignancy | (BNT162b2 (Pfizer/BionTech)) or (mRNA-1273 (Moderna)) |
Eliakim-Raz, N. | Israel | Prospective cohort | 161 | 95 | 58 | 65 [56–72]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Firket, L. | USA | Retrospective cohort | 40 | 20 | 45 | 51.2 | Transplant | BNT162b2 (Pfizer/BionTech) |
Furer, V. | Israel | Prospective Cohort | 807 | 686 | 30.7 | 59 [19–88]* | Autoimmune | BNT162b2 (Pfizer/BionTech) |
Gavriatopoulou, M. | Greece | Prospective cohort | 271 | 58 | 48.2 | 75 [63–81]* | Malignancy | BNT162b2 (Pfizer/BionTech) or AZD1222 vaccine (ASTRAZENECA/OXFORD) |
Geisen, UM. | Germany | Retrospective cohort | 68 | 42 | 35.7 | 50.5 | Autoimmune | BNT162b2 (Pfizer/BionTech) or mRNA-1273 (Moderna) |
Ghandili, S. | Germany | Retrospective cohort | 82 | 82 | 59.8 | 67.5 [40–85] * | Malignancy | mRNA or AZD1222 (ASTRAZENECA/OXFORD) |
Goshen-Lago, T. | Israel | Prospective cohort | 493 | 232 | 57 | 66 | Malignancy | BNT162b2 (Pfizer/BionTech) |
Grupper, A. | Israel | Retrospective cohort | 151 | 136 | 81.7 | 58.6 | Transplant | BNT162b2 (Pfizer/BionTech) |
Hagin, D. | Israel | Prospective cohort | 26 | 26 | 42.4 | 48.4 | Hereditary or Acquired immunodeficiency | BNT162b2 (Pfizer/BionTech) |
Hall, V. G. | Canada | Prospective cohort | 127 | 127 | 69.3 | 66.2 [63.4-70.6] * | Transplant | mRNA-1273 (Moderna) |
Harrington, P. | UK | Retrospective cohort | 21 | 21 | 33.3 | 52.4 | Malignancy | BNT162b2 (Pfizer/BionTech) |
Haskin, O. | Israel | Prospective cohort | 52 | 38 | 66 | 18.6 ± 2.8 | Transplant | BNT162b2 (Pfizer/BionTech) |
Havlin, J. | Czech Republic | Prospective cohort | 48 | 48 | 60.4 | 52.1 ± 14.3 | Transplant | BNT162b2 (Pfizer/BionTech) |
Herishanu, Y. | Israel | Prospective cohort | 219 | 167 | 67.1 | 71 [63–76]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Herrera, S. | Spain | Prospective cohort | 104 | 104 | 79.8 | 60* | Transplant | mRNA-1273 (Moderna) |
Herzog Tzarfati, K. | Israel | Prospective cohort | 423 | 315 | 0.56 | 71 [61–78]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Hod, T. | Israel | Prospective cohort | 322 | 120 | 80 | 59.7 ± 13 | Transplant | BNT162b2 (Pfizer/BionTech) |
Holden, I.K. | Denmark | Prospective cohort | 80 | 79 | 55 | 58.9 [47.9-66.8]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Iacono, D. | Italy | Cross-sectional | 108 | 36 | 41.6 | 82* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Itzhaki Ben Zadok, O. | Israel | Prospective cohort | 39 | 39 | 83 | 61 [44–69]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Karacin, C. | Turkey | Prospective cohort | 47 | 47 | 61.7 | 73 [64–80]* | Malignancy | CoronaVac |
Kennedy, NA. | UK | Prospective cohort | 1293 | 1293 | NA | NA | Autoimmune | n  = 589 (BNT162b2 (Pfizer/BionTech)) or n  = 704 )ChAdOx1 or AZD1222 (ASTRAZENECA/OXFORD)) |
Korth, J. | Germany | Prospective cohort | 46 | 23 | 48 | 57.7 | Transplant | BNT162b2 (Pfizer/BionTech) |
Malard, F. | France | Retrospective cohort | 225 | 195 | 60 | 68.9* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Marinaki, S. | Greece | Prospective cohort | 150 | 34 | 79.4 | 60 [49.1-68.4]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Massarweh, A. | Israel | Prospective cohort | 180 | 102 | 57 | 66 [56–72]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Mazzola, A. | France | Retrospective cohort | 168 | 143 | 71.3 | 61 [55–67]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Medeiros-Ribeiro, A. C. | Brazil | Prospective cohort | 1092 | 910 | 23.1 | 51 [40–60]* | Autoimmune | CoronaVac |
Monin, L. | UK | Prospective cohort | 205 | 151 | 52 | 73 [64.5-79.5]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Narasimhan, M. | USA | Retrospective cohort | 73 | 73 | 74 | 65 [53.5-69.5]* | Transplant | n  = 48 (BNT162b2 (Pfizer/BionTech)) or n  = mRNA-1273 (Moderna) |
Noble, J. | France | Prospective cohort | 57 | 57 | 68.5 | 62 ± 13 | Transplant | mRNA-1273 (Moderna) |
Ou, M. T. | USA | Prospective cohort | 609 | 585 | 40 | 58 [45–68]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Palich, R. | France | Retrospective cohort | 135 | 110 | 40 | 66 [54–74]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Peled, Y. | Israel | Prospective cohort | 77 | 77 | 64 | 62 [49–68]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Pimpinelli, F. | Italy | Prospective cohort | 128 | 92 | 53.2 | 70 [28–80]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Prendecki, M. | UK | Prospective cohort | 119 | 119 | 52.1 | 52 [39.9-63.9]* | Autoimmune | n  = 85 (BNT162b2 (Pfizer/BionTech)) or n  = 34 (ChAdOx1 or AZD1222 (ASTRAZENECA/OXFORD)) |
Rabinowich, L. | Israel | Cross-sectional | 105 | 80 | 70 | 60.1 | Transplant | BNT162b2 (Pfizer/BionTech) |
Rashidi-Alavijeh, J. | Germany | Prospective cohort | 63 | 43 | 60.5 | 57 [49–64]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Reuken, P. | Germany | Prospective cohort | 55 | 28 | 53.6 | 42 [36–59]* | Hereditary or Acquired immunodeficiency | BNT162b2 (Pfizer/BionTech) |
Rincon-Arevalo, H. | Germany | Prospective cohort | 75 | 40 | 70 | 62.4 [51.25-69.5]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Rozen-Zvi, B. | Israel | Prospective cohort | 308 | 308 | 64 | 57.5 ± 13.8 | Malignancy | BNT162b2 (Pfizer/BionTech) |
Ruddy, J. A. | USA | Prospective cohort | 404 | 404 | 4 | 44 [36–57]* | Autoimmune | BNT162b2 (Pfizer/BionTech) |
Sattler, A. | Germany | Prospective cohort | 78 | 39 | 71.8 | 57.3 | Transplant | BNT162b2 (Pfizer/BionTech) |
Schramm, R. | Germany | Prospective cohort | 100 | 50 | 64 | 55 ± 10 | Transplant | BNT162b2 (Pfizer/BionTech) |
Seyahi, E. | Turkey | Cross-sectional | 382 | 82 | 35.4 | 42.2 ± 10 | Autoimmune | BBIBP-CorV (Sinopharm) |
Strauss, A. | USA | Prospective cohort | 161 | 161 | 43 | 64 [48–69]* | Transplant | BNT162b2 (Pfizer/BionTech) or mRNA-1273 (Moderna) |
Stumpf, J. | Germany | Prospective cohort | 3100 | 368 | 65.5 | 57.3 ± 13.7 | Transplant | n  = 103 (BNT162b2 (Pfizer/BionTech)) or n  = 265 (mRNA-1273 (Moderna)) |
Stumpf, J. | Germany | Prospective cohort | 71 | 48 | 63 | 57±14.4 | Transplant | BNT162b2 (Pfizer/BionTech) |
Terpos, E. | Greece | Prospective cohort | 152 | 48 | 60.4 | 83* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Terpos, E. | Greece | Prospective cohort | 59 | 59 | 61 | 66 [61–76]* | Malignancy | BNT162b2 or AZD1222 |
Terpos, E. | Greece | Prospective cohort | 502 | 276 | 54.7 | 74 [62–80]* | Malignancy | BNT162b2 or AZD1222 |
Thakkar, A. | USA | Retrospective cohort | 200 | 200 | 42 | 67 [27–90]* | Malignancy | n  = 180 (mRNA vaccines) or n  = 20 (AD26.COV2.S) |
Werbel, WA. | USA | Retrospective cohort | 30 | 30 | 43.3 | 57 [44–62]* | Transplant | n  = 17 (BNT162b2 (Pfizer/BionTech)) or n  = 13 (mRNA-1273 (Moderna)) |
Yanay, NB. | Israel | Retrospective cohort | 204 | 204 | 63.8 | 57.7 [49.4-67.5]* | Transplant | BNT162b2 (Pfizer/BionTech) or mRNA-1273 (Moderna) |
Yi, SG. | USA | Prospective cohort | 176 | 145 | NA | NA | Transplant | BNT162b2 (Pfizer/BionTech) or mRNA-1273 (Moderna) |